Dinaciclib is primarily used in cancer research and treatment development due to its ability to inhibit cyclin-dependent kinases (CDKs), particularly CDK1, CDK2, CDK5, and CDK9. By blocking these kinases, it disrupts cell cycle progression and reduces the expression of short-lived oncoproteins, leading to apoptosis in tumor cells. It has shown promising activity in preclinical and clinical studies against hematologic malignancies such as chronic lymphocytic leukemia (CLL) and multiple myeloma. Additionally, Dinaciclib has been investigated for solid tumors including melanoma and non-small cell lung cancer. Its mechanism allows for targeting rapidly dividing cancer cells with potential use in combination therapies to enhance efficacy or overcome resistance to other anticancer agents.